A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy, safety, and pharmacokinetics of GW906 Injection used as add-on therapy in patients with hypertension not adequately controlled by one or two antihypertensive medications.

Participants are randomized to receive either GW906 Injection or placebo for 6 months.

Inclusion criteria

• Age ≥ 18 years, of either sex.
• Treated hypertension on stable therapy with up to 1 or 2 antihypertensive medications. Stable therapy is defined as having no change in antihypertensive medication or dose within 4 weeks prior to randomization.
• Mean sitting systolic blood pressure (msSBP) ≥ 140 mmHg and < 180 mmHg at the randomization visit.
• Willing to participate in the study and provide written informed consent.

Exclusion criteria

• Secondary hypertension.
• orthostatic hypotension.
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5× upper limit of normal (ULN); Total bilirubin > 1.5 × ULN; International normalized ratio (INR) > 2.0; Serum potassium > 5.0 mmol/L or < 3.5 mmol/L; eGFR≤30 mL/min/1.73m^2.
• Received an investigational agent within the last 3 months.
• Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus.
• History of any cardiovascular event within 12 months.
• History of intolerance to SC injection(s).